Physician profile
Rudin Gjeka
NPI 1851734164
$10,248.96
in general payments reported to CMS, 2019-2025
32 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,115 · 2020: $1,916 · 2021: $462 · 2022: $1,034 · 2023: $361 · 2024: $1,163 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331 · Travel and Lodging: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,331.13 |
| Travel and Lodging | $389.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,009.27 | 2019-2023 | Watchman Access System |
| Medtronic Vascular, INC. | $1,881.53 | 2019-2020 | |
| Edwards Lifesciences Corporation | $1,303.78 | 2019-2024 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $1,156.48 | 2019-2022 | |
| Endologix LLC | $606.91 | 2024-2025 | Torus Stent Graft System, Endocross Device, Alto Abdominal Stent Graft System |
| Novartis Pharmaceuticals Corporation | $415.70 | 2019-2025 | |
| W. L. Gore & Associates, INC. | $389.65 | 2025 | Gore Cardioform Asd Occluder |
| Medtronic, INC. | $315.74 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.53 | 2024-2025 | Jardiance |
| Inari Medical, INC. | $251.47 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Lexicon Pharmaceuticals, INC. | $210.55 | 2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $175.00 | 2022-2025 | Camzyos, Eliquis |
| Teleflex LLC | $157.77 | 2024 | Manta |
| Sanofi-Aventis U.S. LLC | $141.99 | 2019-2023 | |
| Abiomed | $123.47 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.38 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $105.75 | 2019-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $103.38 | 2024 | Assure Wcd |
| Pfizer INC. | $85.63 | 2021-2024 | |
| Baxter Healthcare | $73.38 | 2022 | |
| Cleerly, INC. | $63.92 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Astrazeneca Pharmaceuticals LP | $40.00 | 2019-2022 | |
| Tactile Systems Technology INC | $28.39 | 2025 | Flexitouch Plus, Nimbl |
| Philips North America LLC | $28.13 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $26.31 | 2024 | Arcalyst |
| Smith+Nephew, INC. | $24.97 | 2025 | Pico 7 |
| Cardiva Medical, INC. | $24.49 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Amarin Pharma, INC. | $20.58 | 2021 | |
| Amgen INC. | $17.20 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.16 | 2020 | |
| Ekos Corporation | $12.54 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudin Gjeka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.